Comparison of SP263 and 22C3 immunohistochemistry PD-L1 assays for clinical efficacy of adjuvant atezolizumab in non-small cell lung cancer: results from the randomized phase III IMpower010 trial.

Caicun ZhouMinu K SrivastavaHao XuEnriqueta FelipHeather WakeleeNasser AltorkiMartin ReckRüdiger LierschAnna KryzhanivskaSatoshi OizumiHiroshi TanakaJohn HammSteven L McCuneElizabeth BennettBarbara GitlitzVirginia McNallyMarcus BallingerMark McClelandWei ZouMeghna Das ThakurSilvia Novello

Published in: Journal for immunotherapy of cancer (2023)

NCT02486718.

Keyphrases

phase iii
open label
double blind
clinical trial
placebo controlled
phase ii
early stage
high throughput
study protocol
randomized controlled trial
single cell
clinical evaluation